EQ 300

Boldenone Undecylenate — EQ 300 by Dragon Pharma

EQ 300 is Dragon Pharma's formulation of injectable Boldenone Undecylenate at 300mg/ml — originally developed as a veterinary steroid for horses, Boldenone is structurally a testosterone molecule with an added 1,2-double bond that fundamentally changes its behaviour in the human body. Each 10ml vial in Dragon Pharma's MCT oil carrier provides sustained release over its long Undecylenate ester, suited to extended cycles of 14 weeks or more.

Also searched as: Boldenone Undecylenate 300mg, EQ 300, Equipoise Dragon Pharma, Boldenone steroid.

What Is Boldenone Undecylenate (Equipoise)?

Boldenone is structurally testosterone with a C1-C2 double bond added — a modification that produces several important differences from testosterone despite structural similarity:

The RBC Elevation Mechanism — EQ's Most Distinctive Property

Boldenone's pronounced stimulation of red blood cell production (erythropoiesis) is its most clinically distinctive property and a genuine information gap in most competitor content:

• Boldenone stimulates erythropoietin (EPO) production in the kidneys — the same mechanism as exogenous EPO used in endurance sports
• The resulting increase in red blood cell count and haematocrit improves oxygen delivery to muscle tissue, contributing to improved endurance and training capacity alongside its anabolic effects
• This haematocrit elevation is dose-dependent — at higher doses or longer cycles, haematocrit can reach levels requiring intervention (blood donation is sometimes used to manage this)
• Haematocrit above ~52-54% is associated with increased blood viscosity and cardiovascular risk — monitoring via bloodwork is more important with EQ than with most other injectable compounds
• This unique mechanism is why EQ appears in WADA testing for endurance-enhancement alongside its use as an anabolic AAS

Why EQ Requires Longer Cycles Than Most Injectable Steroids

The Undecylenate ester is longer than the commonly used Enanthate or Cypionate esters — approximately 14 days versus 7-8 days half-life:

• Time to reach steady-state blood levels = approximately 4-5 × half-life = 56-70 days (8-10 weeks) just to stabilise
• A 10-week cycle leaves only ~2 weeks of work at stable levels — most experienced EQ users run 14-16 weeks minimum
• Many users start EQ several weeks before other long-ester compounds specifically to account for its slow build
• Conversely, EQ blood levels remain detectable for an extended period after stopping — the WADA detection window for Boldenone is among the longest of any AAS, documented at 5+ months in some cases

Effects and Benefits

• Steady, gradual lean mass gains with lower water retention than testosterone at equivalent doses
• Pronounced appetite stimulation — one of the most significant appetite increases of any AAS, making EQ particularly useful in caloric surplus phases
• Improved endurance and work capacity through RBC elevation and increased haematocrit
• Lower androgenic activity than testosterone — favourable anabolic-to-androgenic ratio
• Lower aromatisation rate than testosterone, reducing estrogen management demands